Monthly Prescribing Reference
   
Subscribe to our RSS feeds RSS | Login | Register
  • HOME
  • SPECIALTY
    • Hematology-Oncology
    • Long Term Care
    • Nurse Practitioners
    • OB/GYN
    • Pharmacists
    • Physician Assistants
    • Primary Care Physicians
    • Residents
    • Urologists
  • THERAPEUTIC CATEGORIES
  • BRAND
  • GENERIC
  • COMPARE
  • NEWS
    • Drug News
    • Drugs in the Pipeline
    • Drug Safety Alerts and Recalls
    • New Drug Products
    • Polls & Surveys
    • Newsletters
    • News from Haymarket Journals
  • RESOURCES
    • Alerts (Sponsored)
    • Clinical Charts
    • Common Medical Abbreviations
    • Company
    • Drug Monograph Format
    • FDA Orange Book
    • Pharmacology Notes
    • Professional Associations
    • Video
    • Blogs
    • MPR Publications
    • Customer Service
    • Online Banner Ad Specs
    • Subscribe
  • DOWNLOAD
  • CME
  • JOBS
  • #
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
Home > Manufacturers > M > Medicis Pharmaceuticals Corp

Medicis Pharmaceuticals Corp

 

Address:

8125 North Hayden Road
Scottsdale, AZ 85258-2463

Email:

NA

Website:

click to visit

Phone:

(800) 550-5115

Fax:

(602) 808-0822

 
Compare | Add to Clipboard | View Clipboard
Name Section Compare
AMMONUL
Nutrition > Inborn errors of metabolism
compare
DYNACIN
Dermatological Disorders > Acne
compare
Infections & Infestations > Bacterial infections
compare
LIDEX
Dermatological Disorders > Topical steroids
compare
LIDEX-E CREAM
Dermatological Disorders > Topical steroids
compare
LOPROX
Dermatological Disorders > Skin infections (topicals)
compare
LOPROX GEL
Dermatological Disorders > Skin infections (topicals)
compare
LOPROX SHAMPOO
Dermatological Disorders > Skin infections (topicals)
compare
LUSTRA
Dermatological Disorders > Miscellaneous dermatological conditions
compare
LUSTRA-AF
Dermatological Disorders > Miscellaneous dermatological conditions
compare
SOLODYN
Dermatological Disorders > Acne
compare
SYNALAR
Dermatological Disorders > Topical steroids
compare
SYNALAR OINTMENT
Dermatological Disorders > Topical steroids
compare
SYNALAR SOLUTION
Dermatological Disorders > Topical steroids
compare
TRIAZ
Dermatological Disorders > Acne
compare
TRIAZ CLEANSER
Dermatological Disorders > Acne
compare
TRIAZ PADS
Dermatological Disorders > Acne
compare
VANOS
Dermatological Disorders > Topical steroids
compare
ZIANA
Dermatological Disorders > Acne
compare
  • Most Popular
  • Most Emailed
  • Most Recent
  • FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
  • Xiaflex available for Dupuytren's contracture
  • Pediaderm HC Complete Kit available for atopic dermatitis
  • Botox approved for upper limb spasticity
  • Trelstar 22.5mg approved for palliative treatment of prostate cancer
  • New Product: SAPHRIS® (asenapine) Sublingual Tablets
  • Generic timolol maleate ophthalmic gel forming solution available
  • FDA warns of intravascular hemolysis risk with WinRho SDF
  • Five-day dosing regimen for Dacogen approved for myelodysplastic syndromes (MDS)
  • FDA accepts NDA for lurasidone, a treatment for schizophrenia
  • Recommended Adult Immunization Schedule
  • FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
  • Prevnar 13 pneumococcal disease vaccine approved
  • Hizentra approved for primary immunodeficiency
  • Kapidex to be marketed under new trade name Dexilant
  • FDA grants priority review to Tasigna for newly diagnosed chronic myeloid leukemia
  • FDA accepts NDA for JZP-6, a treatment for fibromyalgia
  • Rituxan approved for chronic lymphocytic leukemia
  • Victoza available for type 2 diabetes
  • Pediaderm HC Complete Kit available for atopic dermatitis
  • Five-day dosing regimen for Dacogen approved for myelodysplastic syndromes (MDS)
  • FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
  • Trelstar 22.5mg approved for palliative treatment of prostate cancer
  • FDA accepts NDA for lurasidone, a treatment for schizophrenia
  • FDA warns of intravascular hemolysis risk with WinRho SDF
  • Botox approved for upper limb spasticity
  • New Product: SAPHRIS® (asenapine) Sublingual Tablets
  • Pediaderm HC Complete Kit available for atopic dermatitis
  • Generic timolol maleate ophthalmic gel forming solution available
  • Xiaflex available for Dupuytren's contracture
Sponsored Links

MPR SITEMAP


Search our Drug Database

Browse by Brand
Browse by Generic
Browse by Manufacturer
Browse by Therapeutic Category

News

News
Drug News
New Drug Products
Polls & Surveys
Newsletters

Clinical Charts

Clinical Charts

Resources

Resources
Pharmacology Notes
Alerts (Sponsored)

Therapeutic Categories

Allergic Disorders
Cardiovascular System
Central Nervous System
Dental
Dermatological Disorders
Diagnostic Agents
Ear Disorders
Endocrine System
Eye Disorders
Gastrointestinal Tract
Hematology
Immune System
Infections & Infestations
Musculoskeletal Disorders
Neoplasms
Nutrition
OB/GYN
Pain & Pyrexia
Poisoning & Drug Dependence
Respiratory Tract
Urogenital System

More

Customer Service
Subscribe
Advertise
About Us
Permissions
MPR Publications
Disclaimer
Subscribe to our RSS feeds RSS


Other Haymarket Medical Websites


Cortlandt Forum

Clinical Advisor

Renal and Urology News

JAAPA

myCME - Online CME

McKnights Long Term Care News

International

healthcare republic

MIMS (drug database)
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions